EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSNFUG00015010218
Gene Symbol: PSMD13
3 Cross references
216 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSNFUG00015003880
Gene Symbol: PSMD14
3 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 2

Ensembl ID : ENSNFUG00015013564
Gene Symbol: PSMD2
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSNFUG00015023918
Gene Symbol: PSMD6
3 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSNFUG00015019333
Gene Symbol: PSMD7
3 Cross references
235 Possible Orthologues:

Proteasome Subunit Alpha Type-6

Ensembl ID : ENSNFUG00015017878
Gene Symbol: LOC107396026
3 Cross references
278 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSNFUG00015007228
Gene Symbol: PSMB11
1 Cross references
169 Possible Orthologues:

Proteasome Subunit Beta Type-6-Like

Ensembl ID : ENSNFUG00015009135
Gene Symbol: LOC107372744
3 Cross references
230 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSNFUG00015007261
Gene Symbol: PRMT5
1 Cross references
198 Possible Orthologues:

Protein Farnesyltransferase Subunit Beta-Like

Ensembl ID : ENSNFUG00015003237
Gene Symbol: LOC107377823
3 Cross references
209 Possible Orthologues:

Protein Kinase C Alpha Type

Ensembl ID : ENSNFUG00015004518
Gene Symbol: LOC107391584
3 Cross references
213 Possible Orthologues:

Protein Kinase C Beta

Ensembl ID : ENSNFUG00015001024
Gene Symbol: PRKCB
1 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).